A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells

The aim of this study is to investigate the mechanisms of interactions between TGF-beta and Wnt/beta-catenin pathways that induce and regulate EMT and promote breast cancer cells to become resistant to treatment. The effect of TGF-beta on Wnt/beta-catenin signaling pathway was examined by using a human Wnt/beta-catenin-regulated cDNA plate array and western blot analysis. The interaction of Twist at promoter of Wnt3 was examined by chromatin immunoprecipitation (ChIP) assay. Secreted Wnt3 level was determined by ELISA assay. HER2-overexpressing breast cancer cells treated with TGF-beta have a reduced response to trastuzumab and exhibited EMT-like phenotype. The TGF-beta-induced EMT in HER2-cells was concordant with upregulation of Wnt3 and beta-catenin pathways. The TGF-beta-induced induction of Wnt3 during EMT was found to be Smad3-dependent. ChIP analysis identified occupancy of Twist at promoter region of Wnt3. Knock-down of Twist by shRNA confirmed the significance of Twist in response to TGF-beta regulating Wnt3 during EMT. Subsequently, TGF-beta-induced matrix metalloproteinases, MMP1, MMP7, MMP9, MMP26, Vascular endothelial growth factors (VEGF), and activation of Wnt/beta-catenin signaling were repressed by the shRNA treatment. TGF-beta R1 ALK5 kinase inhibitor, A83-01 can effectively prevent the TGF-beta-induced Twist and Wnt3. Co-treating A83-01 and trastuzumab inhibited TGF-beta-induced cell invasion significantly in both trastuzumab responsive and resistant cells. Our data demonstrated an important interdependence between TGF-beta and Wnt/beta-catenin pathways inducing EMT in HER2-overexpressing breast cancer cells. Twist served as a linkage between the two pathways during TGF-beta-induced EMT. A83-01 could inhibit the TGF-beta-initiated pathway interactions and enhance HER2-cells response to trastuzumab treatment.